Effect of HA on hematopoietic recovery in tumor-bearing mice.

Slides:

Advertisements

Similar presentations

A, Effect of folate-FITC (500 nmol/kg, 5 days/week) and/or sunitinib (20 mg/kg daily) therapy on the growth of M109 tumors in Balb/c mice. A, Effect of.

Advertisements

SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.

Selinexor combines with immune checkpoint blockade to slow B16F10 melanoma tumor growth. Selinexor combines with immune checkpoint blockade to slow B16F10.

T3 increased J7-TRα1 cell migration and proliferation both in vitro and in vivo. T3 increased J7-TRα1 cell migration and proliferation both in vitro and.

In vivo retroviral gene transfer by direct intrafemoral injection results in correction of the SCID phenotype in Jak3 knock-out animals by Christine S.

by Gerald de Haan, Willem Nijhof, and Gary Van Zant

BV6 increases tumor burden in bone.

H31m1-PDL1 cells form progressively growing tumors in WT mice.

HER2 mutants V777L, G309A, D769H formed tumors more rapidly than HER2 WT. A, a total of 0.5 × 106 cells of NIH3T3 expressing either HER2 WT or mutant were.

Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.

Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells by Xiaoli Wang, Cing Siang Hu, Bruce Petersen, Jiajing.

Lack of correlation between an assay used to determine early marrow allograft rejection and long-term chimerism after murine allogeneic bone marrow transplantation:

Immunologic and hematopoietic effects of recombinant human prolactin after syngeneic bone marrow transplantation in mice Rui Sun, Ruth A Gault, Lisbeth.

Activity of MAC-321 (i. v. and p. o

Erythroid progenitor capacity of Epo transgenic mice.

Senescence-associated inflammation, bone marrow suppression, and cardiac dysfunction. Senescence-associated inflammation, bone marrow suppression, and.

Gene expression changes associated with response to combination CPI-444 and anti–PD-L1 treatment in MC38 tumors. Gene expression changes associated with.

C-MYC controls expression of ABC drug transporters in CD34+ hematopoietic progenitors. c-MYC controls expression of ABC drug transporters in CD34+ hematopoietic.

PTENP1 serves as a ceRNA in the regulation of tumor growth in RCC

Leukemic blasts express a “hypoxia signature

PTENP1 sensitizes renal cancer cells to chemotherapy.

Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model in vivo. Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model.

GS87 demonstrates efficacy in a circulating AML mouse model system.

NSG mice transplanted with human primary ALK-positive ALCL tumor grafts were administered either doxorubicin, 10 mg/kg i.v. or CEP orally, 100 mg/kg,

coTCRcys-transduced T cells control tumor growth in vivo.

CDDO-Me induces apoptosis independent of Bcl-2 level as well as p53 status in human NSCLC cells. CDDO-Me induces apoptosis independent of Bcl-2 level as.

The selective depletion of DTR-expressing FAP+/CD45+ and FAP+/CD45− tumoral cells from bone marrow chimeric mice by the administration of DTX. A, sketch.

Colony-forming capacity of CD34+ cells with and without CLL-1 expression. Colony-forming capacity of CD34+ cells with and without CLL-1 expression. CD34+

Survival and tumor burden of mice bearing peritoneally disseminated gastric cancer. Survival and tumor burden of mice bearing peritoneally disseminated.

PRIMA-1Met inhibits the growth of multiple myeloma tumors with mutant p53 in vivo. PRIMA-1Met inhibits the growth of multiple myeloma tumors with mutant.

Effects of WDL on in vitro invasion and soft agar colony formation by LNCaP cells. Effects of WDL on in vitro invasion and soft agar colony formation by.

TSA-mediated changes in cell cycle inhibitor proteins.

Accelerated metastasis spread in tumor-bearing mice treated with paclitaxel and anakinra. Accelerated metastasis spread in tumor-bearing mice treated with.

Anti-Flk-1 treatment inhibits growth of s. c. 4T1 and B16 tumors. s. c

Active AR signaling in enzalutamide-resistant xenograft tumors.

PD-L1 expressed on edited T3 sarcoma cells prevents their immune elimination. PD-L1 expressed on edited T3 sarcoma cells prevents their immune elimination.

SAF-1 expression in clinical breast cancer tissues.

Endothelial cells/microvasucles are increased in prostate cancer versus normal tissues. Endothelial cells/microvasucles are increased in prostate cancer.

Angiogenesis in tumors formed by cells varying in the expression of CXCR2. Angiogenesis in tumors formed by cells varying in the expression of CXCR2. A,

GA reduces the growth of Caki-1 tumor xenografts.

In vivo tumorigenicity of MKN-1 cells with sustained suppression of HDAC2. In vivo tumorigenicity of MKN-1 cells with sustained suppression of HDAC2. A,

Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth and metastasis. Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth.

Colony formation of K-562 cells after 24 h (upper panel) or 48 h (lower panel) exposure to ErPC3 (20 μm) and ASO-bcr (10 μm), respectively. Colony formation.

Tumor and serum levels of murine IL-12.

Binding and antiproliferative effects of ANG4043 and anti-HER2 mAbs on tumor cells. Binding and antiproliferative effects of ANG4043 and anti-HER2 mAbs.

Endogenously produced n-3 PUFAs inhibit endometrial cancer cell growth in vitro and in vivo. Endogenously produced n-3 PUFAs inhibit endometrial cancer.

Pharmacodynamic evaluation of VT-464 and ABI in MR49F xenograft model.

Micro-PET/CT images of 64Cu-Sar-chTNT-3 in MAD109-bearing BALB/c mice following VP-16 pretreatment. Micro-PET/CT images of 64Cu-Sar-chTNT-3 in MAD109-bearing.

Ki-67 expression in M31- and H3-treated tumors (A) and respective Ki-67 labeling indices in the two groups of tumors (B). Ki-67 expression in M31- and.

Effect of the crystal form and solid dispersion preparations of KRN633 on the growth of human tumor xenografts in mice. Effect of the crystal form and.

A, tumor growth studies in H1975 tumor–bearing mice.

Impairment of liver function upon treatment with 4D5MOCB-ETA.

Essential role for the overexpression of type I IFN-related genes in the improved chemotherapeutic response of Stat3−/− tumors. Essential role for the.

NT157 treatment inhibits LNCaP xenograft growth and delays castration-resistant progression. NT157 treatment inhibits LNCaP xenograft growth and delays.

Effect of SPINDLIN1 protein on cancer cell proliferation and invasion.

Anti-CD40 activates TAMs and recruits inflammatory monocytes.

VEGF165 stimulates migration of HMVECs

SPARC is required for spontaneous metastasis

Increased accumulation of pmel-1 T cells to tumor sites and enhanced antitumor immune response in mice receiving ACT combined with anti-PD-1 antibody treatment.

Proliferation of TA3-Ha and TA3-St cells in vitro and in vivo.

Mutation of the Smad3 linker phosphorylation sites in 4T1 cells reduces putative stem cell population and tumor initiating frequency of cells from the.

Bioluminescent imaging of NALM-6(GFP-FFLuc) tumor cells after weekly CAR+ T-cell treatment for 4 wks. Bioluminescent imaging of NALM-6(GFP-FFLuc) tumor.

Cy5.5-labeled anti-B7-H4 BsAb (Fab-scFv) localization in tumor-bearing mice and BsAb half-life in mouse blood. Cy5.5-labeled anti-B7-H4 BsAb (Fab-scFv)

Transgenic mice with constitutively active NIK show increased tumor growth in bone. Transgenic mice with constitutively active NIK show increased tumor.

BV6 increases bone metastasis.

Validation of KMT2D function in MM23, MM2, and MM25 PDXs

Loss of NQO1 expression inhibits invasion of NSCLC

PD-L1 expression is not associated with PTEN expression status in melanomas. PD-L1 expression is not associated with PTEN expression status in melanomas.

AXL knockout does not prevent dormancy.

DHA and dietary n-3 PUFAs inhibit endometrial cancer cell growth in vitro and in xenograft models. DHA and dietary n-3 PUFAs inhibit endometrial cancer.

Presentation transcript:

Effect of HA on hematopoietic recovery in tumor-bearing mice. Effect of HA on hematopoietic recovery in tumor-bearing mice. A, bone marrow cells (BMC) were collected on day 1 before chemotherapy was started, on day 22 after chemotherapy was terminated, and on days 26 and 30 after HA or PBS injections as described in Materials and Methods (n = 3). The number of BMC per femur was calculated and expressed as a mean ± SD. B, the number of progenitors in each sample was evaluated by colony-forming unit assay (CFU). The number of colonies per femur is shown as mean ± SD. Results from one of two similar experiments. Barbara M. Mueller et al. Mol Cancer Ther 2010;9:3024-3032 ©2010 by American Association for Cancer Research